Trials / Withdrawn
WithdrawnNCT01168882
Safety and Tolerability of RGB-286638 in Patients With Selected, Relapsed or Refractory Hematological Malignancies
Phase 1 Open-label, Dose-escalation Clinical Study of the Safety and Tolerability of RGB-286638, a Novel, Multi-targeted Kinase Inhibitor, Administered to Patients With Selected, Relapsed or Refractory Hematological Malignancies
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Agennix · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine the safety and tolerability of RGB-286638, a novel, multi-targeted kinase inhibitor, administered to patients with selected, relapsed or refractory hematological malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RGB-286638 | The starting dose is a flat-fixed dose of 40 mg given i.v. over 60 min, weekly x3, of a 28-days cycle (q4 weeks) |
Timeline
- Start date
- 2011-11-01
- Primary completion
- 2014-06-01
- Completion
- 2015-07-01
- First posted
- 2010-07-23
- Last updated
- 2012-08-02
Source: ClinicalTrials.gov record NCT01168882. Inclusion in this directory is not an endorsement.